An update from Prime Medicine, Inc. ( (PRME) ) is now available.
On March 18, 2025, Prime Medicine, Inc. announced a preclinical program for treating alpha-1 antitrypsin deficiency (AATD) using its universal liver lipid nanoparticle to edit the SERPINA1 gene mutation. Initial in vivo data showed promising results with up to 72% precise correction of the gene in humanized mice, restoring over 95% of serum AAT to normal levels. The company plans to advance the AATD program through lead optimization and aims to file an investigational new drug application by mid-2026, indicating significant progress in its liver franchise and potential impact on treating both lung- and liver-associated diseases.
More about Prime Medicine, Inc.
Prime Medicine, Inc. operates in the biotechnology industry, focusing on gene editing technologies. The company specializes in Prime Editing, a next-generation gene editing technology, and is advancing various programs targeting genetic diseases such as chronic granulomatous disease, Wilson’s Disease, cystic fibrosis, and alpha-1 antitrypsin deficiency (AATD).
YTD Price Performance: -41.47%
Average Trading Volume: 1,106,996
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $234.8M
For detailed information about PRME stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com